Centre Henri Becquerel

Rouen, France

54 recruiting

Showing 120 of 54 trials

Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled129 locationsNCT06973187
Recruiting
Phase 3

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Johnson & Johnson Enterprise Innovation Inc.30 enrolled11 locationsNCT07219212
Recruiting
Phase 3

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled137 locationsNCT07276399
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled168 locationsNCT06149286
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 3

Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers

Radiotherapy, AdjuvantOral Cavity CarcinomaFlap+1 more
Centre Francois Baclesse348 enrolled25 locationsNCT06798922
Recruiting
Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 3

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled30 locationsNCT05581121
Recruiting
Phase 2

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Low Grade Endometrial Stromal Sarcoma
Centre Leon Berard40 enrolled22 locationsNCT03624244
Recruiting
Phase 3

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma
Institut Claudius Regaud600 enrolled19 locationsNCT04307277
Recruiting
Phase 2

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

Lymphoma, Mantle-Cell
The Lymphoma Academic Research Organisation100 enrolled16 locationsNCT06558604
Recruiting
Not Applicable

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

Brain MetastasisOligoprogression
Centre Francois Baclesse504 enrolled15 locationsNCT05102747
Recruiting
Phase 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
The Lymphoma Academic Research Organisation150 enrolled31 locationsNCT04220970
Recruiting
Phase 2

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Metastatic Renal Cell CarcinomaRadiotherapy
Centre Francois Baclesse77 enrolled30 locationsNCT04299646
Recruiting
Not Applicable

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

CNS Metastases
Jules Bordet Institute600 enrolled17 locationsNCT04109131
Recruiting
Not Applicable

Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Centre Henri Becquerel115 enrolled1 locationNCT06879704